Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

[1] Wang H(2022)Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 Lancet 399 1513-36

[2] Paulson KR(2021)Emerging SARS-CoV-2 variants: genetic variability and clinical implications Curr Microbiol 79 20-1597

[3] Pease SA(2022)Advanced materials for SARS-CoV-2 vaccines Adv Mater 34 e2107781-75

[4] Watson S(2022)COVID-19 vaccination, time for a second breath? EMBO Mol Med 14 e15810-258

[5] Comfort H(2021)Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 npj Vaccines. 6 128-202

[6] Zheng P(2021)Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, phase I trial Emerg Microbes Infect 10 1589-e183

[7] Dubey A(2022)A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity Vaccine 40 2068-1706

[8] Choudhary S(2021)Adjuvanting a subunit COVID-19 vaccine to induce protective immunity Nature 594 253-200

[9] Kumar P(2020)Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant Metab Eng 57 193-66.e4

[10] Tomar S(2020)SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination Adv Mater 32 e2005637-undefined

[1] Wang H(2022)Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 Lancet 399 1513-36

[2] Paulson KR(2021)Emerging SARS-CoV-2 variants: genetic variability and clinical implications Curr Microbiol 79 20-1597

[3] Pease SA(2022)Advanced materials for SARS-CoV-2 vaccines Adv Mater 34 e2107781-75

[4] Watson S(2022)COVID-19 vaccination, time for a second breath? EMBO Mol Med 14 e15810-258

[5] Comfort H(2021)Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 npj Vaccines. 6 128-202

[6] Zheng P(2021)Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, phase I trial Emerg Microbes Infect 10 1589-e183

[7] Dubey A(2022)A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity Vaccine 40 2068-1706

[8] Choudhary S(2021)Adjuvanting a subunit COVID-19 vaccine to induce protective immunity Nature 594 253-200

[9] Kumar P(2020)Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant Metab Eng 57 193-66.e4

[10] Tomar S(2020)SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination Adv Mater 32 e2005637-undefined